-
Innovation Ranking
NewInnovation Ranking – Infinity Pharmaceuticals Inc
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Solid Tumor Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Hypopharyngeal Cancer Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Laryngeal Cancer Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Nasopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Nasopharyngeal Cancer Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Human Papillomavirus (HPV) Associated Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Human Papillomavirus (HPV) Associated Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Human Papillomavirus (HPV) Associated Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Oral Cavity (Mouth) Cancer Drug Details: Eganelisib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Non-Small Cell Lung Cancer Drug Details: Eganelisib is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Triple-Negative Breast Cancer (TNBC) Drug Details: Eganelisib is...